A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage
April 28th, 2022
The present protocol establishes a peritoneal dialysis (PD) mouse model of chlorhexidine gluconate (CG)-induced peritoneal fibrosis. The current model is simple and easy to use compared to other PD animal models.
Establishing animal model for peritoneal dialysis, PD, is very important. We hope it can improve the technology and the efficacy of PD therapy and eventually improve the patient's survival. This peritoneal dialysis mouse model is simple, easy to use, and visible compared to other peritoneal dialysis animal models.
A suitable peritoneal dialysis animal model can help researchers to study the peritoneal, physiological, and the pathological change during PD therapy. Demonstration of the procedure will be Fang-Ling Liao, a research assistant from my laboratory. To begin, prepare the chemical irritant by diluting 0.1%chlorhexidine gluconate in 15%ethanol.
Next, assign three mice as the control group and inject one milliliter per kilogram of 0.9%normal saline intraperitoneally every other day for three weeks for a total of nine times. Then assign three mice to the peritoneal fibrosis group, and induce peritoneal fibrosis by administering an intraperitoneal injection of 0.1%chlorhexidine gluconate solution prepared earlier at a dose of 12.5 microliters per kilogram of the body weight. For peritoneal function tests, prepare a dialysis solution containing 4.25%glucose.
Then use a syringe to draw 0.5 milliliters of dialysate sample. Prepare an injection of zoletil and xylazine and anesthetize the mice by administering an intramuscular injection. Perform intraperitoneal installation of the dialysis solution at a dose of two milliliters per 20 grams of body weight.
Make a small incision in the midline of the abdomen and collect the major intraperitoneal fluid with a syringe. After 30 minutes, perform a vertical incision in the midline of the abdomen beneath the xiphoid process and open the mouse's abdomen to collect the residual intraperitoneal fluid with a syringe. Next, measure the weight of a clean and dry cotton swab.
Put the cotton into the mouse's abdominal cavity to absorb the residual intraperitoneal fluid and then remove it. Measure the cotton weight again. Masson's trichrome staining showed that the parietal peritoneum of the abdominal wall in the chlorhexidine gluconate-exposed group was markedly thicker and fibrotic than the control group.
The visceral peritoneum of the liver surfaces was also significantly thicker and fibrotic in the chlorhexidine gluconate-exposed group than in the control saline group, indicating that peritoneal fibrosis is more severe in the chlorhexidine gluconate-exposed group. The chlorhexidine gluconate-exposed group showed decreased ultrafiltration rate and increased glucose mass transport, indicating that the peritoneal permeability increases in the chlorhexidine gluconate exposed mice While performing an intraperitoneal injection procedure, use the forceps and pick the abdominal skin of the mouse to prevent puncture-induced intraperitoneal organ damage.
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol establishes a peritoneal dialysis (PD) mouse model of chlorhexidine gluconate (CG)-induced peritoneal fibrosis. The model is simple and easy to use compared to other PD animal models.
Key Study Components
Area of Science
- Neuroscience
- Biology
Background
- Establishing animal models for peritoneal dialysis is crucial for research.
- The model aims to improve PD therapy technology and efficacy.
- It helps in studying physiological and pathological changes during PD therapy.
Purpose of Study
- To create a reliable PD mouse model.
- To facilitate research on peritoneal fibrosis.
- To enhance understanding of PD therapy outcomes.
Methods Used
- Dilution of 0.1% chlorhexidine gluconate in 15% ethanol.
- Demonstration of the procedure by a research assistant.
- Utilization of a simple and visible model for ease of use.
- Comparison with other peritoneal dialysis animal models.
Main Results
- Establishment of a straightforward PD mouse model.
- Improved visibility and usability compared to existing models.
- Potential for enhanced research on peritoneal fibrosis.
- Contribution to better understanding of PD therapy.
Conclusions
- The PD mouse model is effective for studying peritoneal fibrosis.
- It provides a foundation for future research in PD therapy.
- Simple protocols can lead to significant advancements in the field.
Frequently Asked Questions
Executive Industry Relevance
Chlorhexidine gluconate-induced peritoneal fibrosis in mice provides a robust preclinical model for evaluating peritoneal dialysis-associated complications. This model enables mechanistic de-risking and supports predictive confidence in translational research targeting peritoneal membrane integrity. Its reproducibility and quantitative outputs position it as a valuable asset for early discovery and preclinical pipeline decisions.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of fibrotic pathway mechanisms relevant to peritoneal dialysis.
- Supports biological de-risking by modeling clinically observed peritoneal fibrosis.
- Facilitates functional target validation for anti-fibrotic interventions.
- Provides predictive confidence for portfolio triage in renal and fibrosis research.
Screening & Assay Development
- Prepares validated disease-relevant systems for compound screening.
- Enables assay standardization through reproducible fibrosis induction and quantifiable endpoints.
- Supports scalability and platform reuse for evaluating multiple therapeutic candidates.
- Delivers reliable quantitative readouts such as ultrafiltration rate and glucose mass transport.
Translational & Preclinical Research
- Aligns with disease-relevant endpoints observed in peritoneal dialysis patients.
- Ensures continuity from discovery through preclinical validation of anti-fibrotic strategies.
- Supports risk-adjusted advancement decisions based on functional and histological outputs.
- Provides mechanistic de-risking for late-stage candidate selection.
Pipeline & Workflow Integration
This model integrates into the discovery-to-preclinical continuum for renal and fibrosis research, supporting both target validation and lead identification workflows.
- Discovery Biology: Enables hypothesis testing of fibrotic mechanisms and pathway clarification in a controlled in vivo setting.
- Screening: Provides assay-ready, reproducible fibrosis endpoints for compound evaluation.
- Analytics: Delivers quantitative measurements such as peritoneal thickness, ultrafiltration rate, and glucose transport for comparative analysis.
- Translational Research: Bridges preclinical findings with clinical relevance by modeling patient-like peritoneal changes.
- Enterprise Reuse: Offers a standardized, reusable platform for cross-program fibrosis and renal research initiatives.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in fibrosis research.
- Operational Value: Enhances standardization, reproducibility, and scalability across studies.
- Strategic Value: Informs go/no-go decisions and improves capital efficiency by de-risking early-stage candidates.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of anti-fibrotic and renal therapeutics.
Implementation Considerations
- Requires expertise in animal handling and peritoneal injection techniques.
- Needs access to histological analysis and functional assay infrastructure.
- Demands cross-team standardization for reproducible fibrosis induction and measurement.
- Adaptation may be necessary for different mouse strains or fibrosis models.
- Limitations include model specificity to peritoneal fibrosis and not other renal pathologies.
